Biochemical characterization of enzyme fidelity of influenza A virus RNA polymerase complex.
BACKGROUND
It is widely accepted that the highly error prone replication process of influenza A virus (IAV), together with viral genome assortment, facilitates the efficient evolutionary capacity of IAV. Therefore, it has been logically assumed that the enzyme responsible for viral RNA replication process, influenza virus type A RNA polymerase (IAV Pol), is a highly error-prone polymerase which provides the genomic mutations necessary for viral evolution and host adaptation. Importantly, however, the actual enzyme fidelity of IAV RNA polymerase has never been characterized.


RESULTS
Here we established new biochemical assay conditions that enabled us to assess both polymerase activity with physiological NTP pools and enzyme fidelity of IAV Pol. We report that IAV Pol displays highly active RNA-dependent RNA polymerase activity at unbiased physiological NTP substrate concentrations. With this robust enzyme activity, for the first time, we were able to compare the enzyme fidelity of IAV Pol complex with that of bacterial phage T7 RNA polymerase and the reverse transcriptases (RT) of human immunodeficiency virus (HIV-1) and murine leukemia virus (MuLV), which are known to be low and high fidelity enzymes, respectively. We observed that IAV Pol displayed significantly higher fidelity than HIV-1 RT and T7 RNA polymerase and equivalent or higher fidelity than MuLV RT. In addition, the IAV Pol complex showed increased fidelity at lower temperatures. Moreover, upon replacement of Mg(++) with Mn(++), IAV Pol displayed increased polymerase activity, but with significantly reduced processivity, and misincorporation was slightly elevated in the presence of Mn(++). Finally, when the IAV nucleoprotein (NP) was included in the reactions, the IAV Pol complex exhibited enhanced polymerase activity with increased fidelity.


CONCLUSIONS
Our study indicates that IAV Pol is a high fidelity enzyme. We envision that the high fidelity nature of IAV Pol may be important to counter-balance the multiple rounds of IAV genome amplification per infection cycle, which provides IAV Pol with ample opportunities to generate and amplify genomic founder mutations, and thus achieve optimal viral mutagenesis for its evolution.
Aggarwal
Shilpa
S
Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, United States of America.
Bradel-Tretheway
Birgit
B
Takimoto
Toru
T
Dewhurst
Stephen
S
Kim
Baek
B
D012321:DNA-Directed RNA Polymerases / Q000737:chemistry / Q000378:metabolism*; D054303:HIV Reverse Transcriptase / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D009980:Influenza A virus / Q000201:enzymology*; D009052:Leukemia Virus, Murine / Q000201:enzymology; D012194:RNA-Directed DNA Polymerase / Q000737:chemistry / Q000378:metabolism; D013379:Substrate Specificity; D014764:Viral Proteins / Q000737:chemistry / Q000378:metabolism
D014764:Viral Proteins; C062210:bacteriophage T7 RNA polymerase; D054303:HIV Reverse Transcriptase; D012194:RNA-Directed DNA Polymerase; D012321:DNA-Directed RNA Polymerases
Biotechniques. 2001 May;30(5):1074-8, 1080, 1082, passim
11355343
Science. 1988 Nov 25;242(4882):1168-71
2460924
J Biol Chem. 2005 Apr 1;280(13):12190-200
15644314
Virol J. 2008 Mar 07;5:40
18325125
J Mol Biol. 2009 Mar 6;386(4):951-61
19150355
J Gen Virol. 2002 Apr;83(Pt 4):723-734
11907320
Retrovirology. 2008 Mar 13;5:26
18339206
Biochemistry. 1992 Feb 4;31(4):954-8
1370910
Biochemistry. 1988 May 31;27(11):3966-74
3415967
J Gen Microbiol. 1954 Jun;10(3):457-64
13174769
FEBS Lett. 1998 Dec 4;440(3):264-7
9872383
Mol Cell Biol. 1989 Feb;9(2):469-76
2469002
J Virol. 1995 Jul;69(7):4012-9
7769659
Virol J. 2007 May 24;4:44
17524144
J Biol Chem. 2007 Jan 12;282(2):1397-408
17090533
Virology. 2005 Apr 25;335(1):106-21
15823610
Methods. 2001 Jul;24(3):218-29
11403571
J Biochem. 1988 Dec;104(6):1021-6
3243763
J Virol. 1998 May;72(5):4224-30
9557711
Biochemistry. 2004 Apr 20;43(15):4490-500
15078095
Nucleic Acids Res. 2003 Mar 15;31(6):1624-32
12626703
J Biol Chem. 1989 Oct 5;264(28):16948-56
2476448
J Gen Virol. 2008 Dec;89(Pt 12):2923-2932
19008377
Biochemistry. 1997 Nov 4;36(44):13718-28
9354643
Proc Natl Acad Sci U S A. 1989 Nov;86(21):8343-7
2479023
Science. 2001 Apr 6;292(5514):7
11292864
JAMA. 1996 Jan 17;275(3):210-6
8604174
J Biol Chem. 1983 Mar 25;258(6):3469-75
6833210
PLoS One. 2009;4(5):e5473
19421324
J Virol. 2003 Jan;77(1):481-8
12477853
J Biol Chem. 2006 Oct 27;281(43):32113-21
16926150
Biochem Biophys Res Commun. 2010 Jan 1;391(1):570-4
19932088
Biochemistry. 1985 Oct 8;24(21):5810-7
3910084
J Virol. 2001 May;75(9):4439-43
11287597
J Virol. 2002 Sep;76(18):8989-9001
12186883
J Biol Chem. 2001 Aug 17;276(33):31179-85
11373286
Arch Virol. 1988;100(3-4):231-44
3401117
DNA Repair (Amst). 2005 Dec 8;4(12):1450-6
16207537
Arch Virol. 1983;77(2-4):223-9
6639357
J Biol Chem. 1987 Apr 25;262(12):5546-53
3553179
Proc Natl Acad Sci U S A. 1984 Dec;81(23):7378-82
6095289
Retrovirology. 2009 Apr 16;6:38
19371434
J Biol Chem. 2003 May 30;278(22):20381-8
12646557
Biochemistry. 2009 Jun 16;48(23):5389-95
19408961
J Virol. 2009 Jan;83(1):29-36
18945782